Since the last competing renewal, the Hematologic Malignancies and Bone Marrow Transplantation Program, formerly the Leukemia-Lymphoma/BMT Program, has greatly expanded in laboratory based and clinical/'translational research. Multiple Investigators have joined the Program and research projects have been Initiated In leukemia biology (the genomics/ proteomics and epigenetic targeting of leukemia and lymphoma), development of targeted therapies for leukemia, myeloma and lymphoma (epigenetic, MDM- 2, Notch/ ubiquitination and/ kinase pathways) and prevention of relapse after allogeneic BMT, In addition, the cutting edge research in basic biology and outstanding translational efforts in hematopoietic stem cells and graft-versus-host disease after BMT have been further expanded. The amount of peer reviewed funding, both federal and non-federal (Leukemia Lymphoma Society, Damon Runyon, etc.) has substantially increased. Peer-reviewed funding has more than doubled from $5.2 million at the last review to $13.4 million, including $2.8 million in NCI funding, in direct funding. Over this grant period, the 36 members of this program from seven departments have published 177 publications of which 25.4% are intra-programmatic and 37.3% are inter-programmatic. Clinical research has benefitted from the recruitment of prominent clinical investigators leading to an increase in Investigator-generated therapeutic studies, We have also expanded collaborations with industry to study novel drugs. Collectively, these Initiatives are leading to enhanced accrual of patients on clinical trials.
The goal of the Hematologic Malignancies/BMT program is to improve the diagnosis and treatment of blood cancers. Including leukemia, lymphoma, and multiple myeloma through translation of high quality, novel basic and clinical research to benefit patients.
Showing the most recent 10 out of 1493 publications
